Teresa Lacosta-Barcina
Leuven, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Drawing on collective action theory to foster sustainable biosimilar markets - insights from co-creation workshops with UK and Belgian stakeholders.
Journal: Expert opinion on biological therapy
Published: March 01, 2025
Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: January 22, 2024
Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: June 05, 2023
Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis.
Journal: Frontiers in pharmacology
Published: August 30, 2022
An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain.
Journal: Frontiers in medicine
Published: August 26, 2022
Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: February 22, 2022
Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
Journal: Frontiers in pharmacology
Published: July 31, 2021
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 07, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026